New features include an injection port for small volume additions, a sub-surface fluid port for either addition or removal, and an extra port for the insertion of a third probe. The enhanced version replaces the first-generation Mobius launched in 2009.
Andrew Bulpin, head of services and solutions, Process Solutions, at EMD Millipore, said the enhanced operational and process monitoring capabilities in the new version would enable operations such as perfusion and monitoring of additional cell culture parameters such as carbon dioxide, viable cell density or optical density.
Designed to replace traditional glass benchtop bioreactors, the Mobius CellReady 3L Bioreactor has a standard stirred-tank format for use in development and optimisation of cell culture processes.
According to Millipore, by eliminating time-consuming steps associated with cleaning, assembly, and sterilisation, the Mobius CellReady 3L bioreactor significantly reduces the turnaround time typically associated with glass bioreactors.
Millipore upgrades Mobius CellReady Bioreactor
Offers increased operational flexibility and enhanced process monitoring
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Semaglutide patent cliff: pharma industry braces for impact
Read moreWith the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing
LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations
Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data. Learn More from LabVantage Leadership at Pittcon 2026
Manufacturing
Schütz to build automated IBC production facility at BASF's Ludwigshafen headquarters
Packaging specialist Schütz has signed an agreement with BASF to construct a highly automated intermediate bulk container manufacturing and storage facility directly adjacent to the chemical giant's main plant in Ludwigshafen, enabling round-the-clock just-in-time delivery
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Manufacturing
SGD Pharma partners with Prince Sterilisation Services for pharmaceutical glass packaging
The pair have already launched the My Sterinity Nasal platform, a new, versatile sterile vial range within SGD Pharma's My Sterinity RTU platform, using the company's U-Save Type I vials, which are designed to support the growing segment of high-value nasal drug delivery